Skip to main content

Table 4 New episodes of GP treatment for substance use problems without and with concurrent specialist treatment, SGP surveillance, Belgium 2016–7 (N = 305)a

From: General practice patients starting treatment for substance use problems: observations from two data sources across levels of care

 GP treatment only (no concurrent treatment)
n = 220
Concurrent specialist treatment
n = 85
Adjusted OR (95% CI) for GP treatment only (n = 259)
 n/N% (95% CI)n/N% (95% CI)
Recently employed113/20754.6 (47.5–61.5)18/7623.7 (14.7–34.8)2.58 (1.36–4.91)
First treatment91/19846.0 (38.9–53.2)13/7916.5 (9.1–26.5)2.78 (1.39–5.55)
Type of substance use
 Street drugs minus cannabis primarily (III-b)37/22016.8 (12.1–22.4)23/8527.1 (18.0–37.8)Removed c
Mono substance use188/22085.5 (80.1–89.8)60/8570.6 (59.7–80.0)Removed c
Recent use of primary substance187/19197.9 (94.7–99.4)54/6188.5 (77.8–95.3)Not included b
 Flemish126/22057.3 (50.4–63.9)64/8575.3 (64.7–84.0)Reference
 Walloon65/22029.5 (23.6–36.0)16/8518.8 (11.2–28.8)1.97 (1.06–3.66)
 Brussels29/22013.2 (9.0–18.4)5/855.9 (1.9–1.3)
  1. Sex, age and age of first use of primary substance were not significantly associated at the univariate level with receiving concurrent specialist treatment or not
  2. Non-overlapping confidence intervals are in bold
  3. a For 9 of 314 patients it was unknown whether they were receiving concurrent specialist treatment
  4. b Recent use of primary substance was not included in the initial multivariate logistic model due to the small number of positive cases
  5. c Variable was removed because it did not significantly improved the fit of the model